NasdaqGS:HCAT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Health Catalyst's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HCAT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.9%

HCAT

2.4%

US Healthcare Services

-0.8%

US Market


1 Year Return

13.9%

HCAT

64.5%

US Healthcare Services

13.8%

US Market

Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned 64.5% over the past year.

Return vs Market: HCAT matched the US Market which returned 13.8% over the past year.


Shareholder returns

HCATIndustryMarket
7 Day4.9%2.4%-0.8%
30 Day17.8%-0.3%-5.7%
90 Day23.5%16.9%8.6%
1 Year13.9%13.9%65.0%64.5%16.4%13.8%
3 Yearn/a101.5%100.0%36.9%27.8%
5 Yearn/a164.7%161.9%85.0%64.2%

Price Volatility Vs. Market

How volatile is Health Catalyst's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Health Catalyst undervalued compared to its fair value and its price relative to the market?

47.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HCAT ($36.03) is trading below our estimate of fair value ($69.07)

Significantly Below Fair Value: HCAT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HCAT is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: HCAT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HCAT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HCAT is overvalued based on its PB Ratio (6x) compared to the US Healthcare Services industry average (5.2x).


Next Steps

Future Growth

How is Health Catalyst forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

11.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HCAT's revenue (17.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: HCAT's revenue (17.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HCAT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Health Catalyst performed over the past 5 years?

65.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: HCAT is currently unprofitable.

Growing Profit Margin: HCAT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if HCAT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare HCAT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HCAT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.8%).


Return on Equity

High ROE: HCAT has a negative Return on Equity (-34.35%), as it is currently unprofitable.


Next Steps

Financial Health

How is Health Catalyst's financial position?


Financial Position Analysis

Short Term Liabilities: HCAT's short term assets ($397.0M) exceed its short term liabilities ($50.2M).

Long Term Liabilities: HCAT's short term assets ($397.0M) exceed its long term liabilities ($182.2M).


Debt to Equity History and Analysis

Debt Level: HCAT's debt to equity ratio (69.9%) is considered high.

Reducing Debt: Insufficient data to determine if HCAT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HCAT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HCAT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Health Catalyst current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HCAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HCAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HCAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HCAT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HCAT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Dan Burton (45 yo)

7.92yrs

Tenure

US$3,519,722

Compensation

Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has many years of strate ...


CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD3.52M) is about average for companies of similar size in the US market ($USD4.61M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Burton
CEO & Director7.92yrsUS$3.52m0.019%
$ 270.3k
Paul Horstmeier
Chief Operating Officer1.92yrsUS$2.53m0.016%
$ 225.4k
Dale Sanders
Chief Technology Officer1.58yrsUS$3.30m0.41%
$ 5.9m
Steven Barlow
Co-Founder & Senior VP12.67yrsno data3.59%
$ 51.4m
Thomas Burton
Co-Founder & Chief Learning Officer12.67yrsno datano data
J. Patrick Nelli
Chief Financial Officer3yrsUS$1.70m0.25%
$ 3.6m
Adam Brown
Senior Vice President of Investor Relationsno datano datano data
Daniel Orenstein
General Counsel & Secretary4.67yrsno data0.10%
$ 1.4m
Trudy Sullivan
Chief Communications and Diversity1.33yrsno datano data
Kyle Salyers
Senior Vice President of Corporate Developmentno datano datano data
Tom Leifsen
Executive Vice President - Salesno datano datano data
Tarah Bryan
Senior Vice President of Marketing1.33yrsno datano data

3.0yrs

Average Tenure

54.5yo

Average Age

Experienced Management: HCAT's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Burton
CEO & Director7.92yrsUS$3.52m0.019%
$ 270.3k
Mark Templeton
Director0.33yrno datano data
John Kane
Independent Director5.67yrsUS$194.05k0.21%
$ 3.1m
Todd Cozzens
Independent Director8yrsUS$42.25k0.71%
$ 10.2m
D. Bullock
Independent Director6.33yrsUS$173.38k0.16%
$ 2.3m
Julie Larson-Green
Independent Director0.67yrno datano data
Michael Dixon
Independent Director9yrsUS$160.01k0.12%
$ 1.8m
Anita Pramoda
Independent Director4.42yrsUS$37.50k0%
$ 0
Duncan Gallagher
Independent Director3.33yrsUS$46.45k0%
$ 0
Timothy Ferris
Director2.67yrsUS$35.00k0.014%
$ 196.2k
S. Smith
Independent Director0.67yrno datano data

4.4yrs

Average Tenure

58yo

Average Age

Experienced Board: HCAT's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.


Top Shareholders

Company Information

Health Catalyst, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Health Catalyst, Inc.
  • Ticker: HCAT
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$1.431b
  • Shares outstanding: 39.71m
  • Website: https://www.healthcatalyst.com

Number of Employees


Location

  • Health Catalyst, Inc.
  • 3165 Millrock Drive
  • Suite 400
  • Salt Lake City
  • Utah
  • 84121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HCATNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2019
2YPDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2019

Biography

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:42
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.